Ишмурзин Г. П., Подольская А. А., Бондарев А. В. ТРОМБОЛИТИЧЕСКАЯ ТЕРАПИЯ У БОЛЬНЫХ ИНФАРКТОМ МИОКАРДА. Российский кардиологический журнал. 2010;(6):56-60.
1. Барбараш О.Л., Кашталап В.В., Воронцова Н.Л. и др. Влияние тромболитической терапии на показатели функции эндотелия у больных инфарктом миокарда // Кардиология. – 2007. – № 10.
2. Калинина С.Г. Сравнительная оценка клинических показателей при тромболитической терапии стрептокиназой и алтеплазой в остром периоде инфаркта миокарда. // Уральский кардиологический журнал. – 2007. – №.1. – С. 51-56.
3. Куприна А.А., Упницкий А.А., Белоусов Ю.Б. Алтеплаза: клиническая фармакология, перспективы применения при остром инфаркте миокарда, фармакоэкономические аспекты // Фарматека. – 2004. – №19-20 (96) – С. 43-46.
4. Ланге Р., Хиллис Д. Реперфузионная терапия при остром инфаркте миокарда // Международный Мед. Журн. – 2002. – № 6. – С. 28-33.
5. Панченко Е.П. Тромболитические препараты в лечении больных острым инфарктом миокарда // Атмосфера. Кардиология. – 2001. – № 1. – С. 16-20.
6. Староверов И.И. Инфаркт миокарда: новые перспективы фибринолитической терапии //Доктор. Ру. – 2004. – № 4. – С. 52-53.
7. Староверов И.И., Коткин К.Л. Опыт применения отечественного тромболитика проурокиназы рекомбинантной (пуро- лаза) в лечении больных острым инфарктом миокарда // Практикующий врач. – 2003. – № 2. – С. 21-22.
8. Чазов Е.И., Матвеева Л.С., Мазаев А.В. и др. Внутрикоронарное назначение фибринолизина при остром инфаркте миокарда // Тер. Арх. – 1976. – Т. 48. – №: 4. – С.8.
9. ACC/AHA Guidelines for the Management of Patients With Acute Myocardial Infarction. 1999 Uptate. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Web version.
10. Alexander K.P., Newby L.K., Armstrong P.W. et al. Acute Coronary Care in the Elderly, Part II: ST-Segment-Elevation Myocardial Infarction: A Scientific Statement for Healthcare Professionals From the American Heart Association Council on Clinical Cardiology: In Collaboration With the Society of Geriatric Cardiology // Circulation. – 2007. – Vol. 115. – P. 2570-2589.
11. Antman, E.M., M. Hand, P.W. Armstrong et al. 2007 focused update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction) // J. Am. Coll. Cardiol. – 2008. – Vol. 51. – P. 210-247.
12. Bueno H., M. Martinez-Selles, E. Perez-David et al. Mechanisms of death in elderly patients with acute myocardial infarction exposed to fibrinolytic therapy: reply, // Eur. Heart J. – 2006. – Vol. 27. – P. 246-248.
13. R. Califf et al. One-Year Results From the Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries (GUSTO-I) Trial. // Circulation. – 1999. – N.94. – 1233-1238.
14. E. Ohman et al. Intravenous Thrombolysis in Acute Myocardial Infarction. In: Sixth ACCP Consensus Conference. //Chest. –2001. – Vol. – 119 (suppl). – P. 253S-277S.
15. Fibrinolytic Therapy Trialists’ (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. // Lancet. – 1994. – N.343. – P. 311–322.
16. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Randomized trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 cases of suspected acute myocardial infarction: ISIS-2. // Lancet. – 1988. – N.2. – P. 349-360.
17. The GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary artery potency, ventricular function and survival after acute myocardial infarction. // N. Engl. J. Med. – 1993. – Vol. 329. – P. 1615-1622.
18. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction// N Engl J Med 1993; 329: 673–682.
19. T. Wall et al. Accelerated plasminogen activator dose regimens for coronary thrombolysis: the TAMI-7 Study Group// JACC 1992;19:482–489.
20. I. Squire et al. Humoral and cellular responses up to 7,5 years after administration of streptokinase for acute myocardial infarction // Eur. Heart J. – 1999. – Vol. 20. – P. 1245–1252.
21. Stenestrand, U. Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA). Fibrinolytic therapy in patients 75 years and older with ST-segmentelevation myocardial infarction: one-year follow-up for large prospective cohort / U. Stenestrand, L. Wallentin // Arch. Intern. Med. – 2003. – Vol. 163. – P. 965-971.
22. TIMI-III B Investigators. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-ST elevation myocardial infarction: results of the TIMI-III B trial // Circulation. – 1994. – VoL 89. – P. 1545–1556.
23. The TIMI Study Group. Comparison of invasive and conservative strategies after treatment with intravenous tissue plasminogen activator in acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) Phase II trial. // N. Engl. J. Med. – 1989. – Vol. 320. – P. 618-627.
24. H. White, F. Van de Werf. Thrombolysis for Acute Myocardial Infarction. //Circulation. – 1998. – Vol. – 97. – P: 1632-1646.
